Evidence map›Paper›PMID 26900640›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2016

Effect of Teriparatide on Bone Formation in the Human Femoral Neck.

Felicia Cosman, David W Dempster, Jeri W Nieves, Hua Zhou, Marsha Zion, Catherine Roimisher, Yvonne Houle, Robert Lindsay, Mathias Bostrom

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Trial
  2. Trial
  3. Trial
  4. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Trial
  5. Trial
  6. The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Article
  12. Article
  13. Article
  14. Histomorphometric changes following treatment for osteoporosis.Journal of endocrinological investigation · 2017
    Article
  15. Review
  16. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Article
  17. Article
  18. Teriparatide and denosumab combination therapy and skeletal metabolism.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Article
  19. Full 24-month treatment course with daily teriparatide: a mechanistic insight.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Felicia CosmanRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
David W DempsterRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Jeri W NievesRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Hua ZhouRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Marsha ZionRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Catherine RoimisherRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Yvonne HouleRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Robert LindsayRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Mathias BostromRegional Bone Center, Helen Hayes Hospital (F.C., D.W.D., J.W.N., H.Z., M.Z., C.R., R.L.), West Haverstraw, New York 10993; Department of Medicine (F.C., R.L.), Department of Pathology (D.W.D.), and Department of Epidemiology (J.W.N.), Columbia University, New York, New York 10032; and Department of Orthopedics (Y.H., M.B.), Hospital for Special Surgery, New York, New York 10021.
Helen Hayes Hospital · USColumbia University · USHospital for Special Surgery · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTeriparatide (TPTD) improves bone mass and microstructure resulting in reduced risk of vertebral and nonvertebral fractures. However, hip bone mineral density improvements are modest and there are no data confirming that TPTD reduces hip fracture risk. To study the effects of TPTD on the proximal femur, we performed a double-blind trial of TPTD vs placebo (PBO) in patients with osteoarthritis from whom femoral neck (FN) samples were obtained at total hip replacement (THR) surgery.

methodsParticipants were randomly assigned to receive TPTD or PBO for an average of 40 days before THR. Double tetracycline labeling was initiated 21 days prior to THR to allow histomorphometric assessment of bone formation. During the THR, an intact sample of the FN was procured, fixed, and sectioned transversely. Serum levels of bone turnover markers were measured at baseline and during the THR. Standard histomorphometric parameters were measured and calculated on four bone envelopes (cancellous, endocortical, intracortical, and periosteal). The primary outcome measure was bone formation rate/bone surface (BFR/BS).

resultsForty individuals were enrolled (25 women, mean age, 71.5 ± 8.0 y and 15 men, mean age, 68.9 ± 7.7 y). In cancellous and endocortical envelopes, BFR/BS was 100% higher in the TPTD vs PBO group (P < .05). Bone turnover markers measured at the time of THR correlated with BFR/BS.

conclusionsTPTD stimulates bone formation rapidly in cancellous and endocortical envelopes of the FN. Our findings provide a mechanistic basis for TPTD-mediated improvement in FN bone mass and ultimately hip strength. This study is the first demonstration of the effect of any osteoporosis medication on osteoblast activity in the human proximal femur.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsDouble-Blind MethodFemaleFemur NeckHumansInsulin ResistanceMaleMiddle AgedOsteogenesisOsteoporosis, PostmenopausalTeriparatideBone Density Conservation AgentsTeriparatide

Identifiers

PMID26900640
PMCPMC4880158
OpenAlexW2286163449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.